---
document_datetime: 2023-09-21 18:29:03
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/tractocile-epar-procedural-steps-taken-authorisation_en.pdf
document_name: tractocile-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3932123
conversion_datetime: 2025-12-20 14:11:10.958206
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company FERRING AB submitted on 6 July 1998 an application for Marketing Authorisation to the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  Antocile,  through  the centralised procedure. During the procedure the name was changed to Atosiban Ferring AB. At the time of the adoption of the Opinion on 23 September 1999 the name was changed again to Tractocile. After agreement by the CPMP on December 1997, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Prof. Silvio Garattini Co-Rapporteur: Dr.Bo Lumholtz/Dr Gorm Jensen

## Licensing status:

A  marketing  authorisation  of  the  same  company  for  this  new  active  substance  outside  the  EEA  is pending  in  Canada,  whereas  the  applicant  in  USA  has  withdrawn  it  (different  clinical  data  and different claimed indications) before the authorisation.

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 24 July 1998.
- The Rapporteur's first assessment report was circulated to all CPMP Members on 12 October 1998.  The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 13 October 1998.
- During the meeting in November 1998 the CPMP agreed on the consolidated list of questions to be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the  company  on 19 November 1998.
- On 26 January 1999, a meeting with the company, the Rapporteurs and the EMEA, took place at the EMEA, in order to clarify some questions.
- The company submitted the responses to the consolidated list of questions on 28 April 1999.
- The Rapporteurs circulated the response assessment report on the company's responses to the list of questions to all CPMP Members on 22 June 1999.
- During  the  meeting  in  July  1999,  the  CPMP  adopted  a  List  of  Outstanding  Issues  including questions to be addressed during an Oral Explanation planned in September 1999. The list of outstanding issue was sent to the Company on 30 July 1999.
- On 6 September 1999, the Company submitted responses to chemical-pharmaceutical issues to be resolved before the Oral Explanation.
- During  the  meeting  on  21-23  September  1999  the  CPMP,  in  the  light  of  the  overall  data submitted,  the  Company's  Oral  Explanation  held  on  21  September  1999  and  the  scientific discussion within the Committee,  issued a positive Opinion  for granting a  Marketing Authorisation to Tractocile on 23 September 1999.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 20 January 2000.